TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03153904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems
Description: MATCH-ADTC (Chorpita \& Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring and Feedback System
Description: For each child, the web-based MFS provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Brief Problem Monitor (BPM) and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all weeks of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring and Feedback System
Description: For each child, the web-based MFS provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Brief Problem Monitor (BPM) and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all weeks of treatment.
Study: NCT02915770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholangiojejunostomy
Description: Half of participants will receive hepatectomy, cholangiojejunostomy and T-tube Drainage,while the other half will receive hepatectomy and T-tube Drainage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-tube
Description: T-tube Drainage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-tube
Description: T-tube Drainage
Study: NCT02898597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Received 8 weekly individualized counseling sessions of cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Received 8 weekly individualized counseling sessions of cognitive behavioral therapy
Study: NCT02214329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor-based exercise training
Description: Body-worn sensors are mounted on different body segments to acquire joint kinematic data and provide real-time joint feedback during exercise training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-home balance training
Description: The control group performs similar exercise as intervention without sensors and with no visual feedback from sensors.
Study: NCT02506868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Weekly sc administration of darbepoetin alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Weekly sc administration of darbepoetin alfa
Study: NCT04023032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent cognitive intervention
Description: The intervention takes place in groups of 6-10 participants and is leaded by one occupational therapist. It includes 16 sessions, 90 minutes each.~The first part of each session starts with a 15-minute review of previous homework or relaxation. The second part, which lasts 35 minutes, involves structured training with activity-sheets, board games, role-playing and computerized games. The third part, which lasts 30 minutes, is the lifestyle interventions. The instructor explains the generalization of the previous activities toward daily life, and introduces healthy lifestyles. Through group discussions, the therapist guides participants to develop solutions and strategies for their memory or cognition-related problems and application to daily life. The last 10 minutes are used to suggest homework.
Study: NCT00985387

Intervention type: DRUG
Intervention: Solifenacin
Description: oral
Study: NCT01567917

Intervention type: PROCEDURE
Intervention: CRC surgery
Description: Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)~- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE

Intervention type: PROCEDURE
Intervention: CRC surgery
Description: Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)~- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE
Study: NCT04303806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: receive rosuvastatin orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: receive rosuvastatin orally once daily.
Study: NCT03005496

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: included in intervention arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: included in intervention and control arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine
Description: included in intervention and control arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beta Carotene
Description: included in intervention arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: included in intervention arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: included in intervention and control arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: included in intervention and control arm
Study: NCT02535767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.
Study: NCT02387671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device: FitBit Flex wrist band
Description: Participants will track their daily steps walked and hours of sleep by wearing the FitBit Flex wrist band during the 8 week study period. The data collected from the wrist band will be synced to participants' FitBit smart phone application and monitored by the study team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device: FitBit Aria weight scale
Description: Participants will record their daily body weight during the 8 week study period by stepping on the FitBit Aria weight scale. The data collected from the scale will be synced to participants' FitBit smart phone application accounts and monitored by the study team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Intake Messages
Description: The study team will send participants daily text messages regarding their dietary intake. Each message will contain five questions that yield a yes, or no response. Messages will be sent daily during the 8 week study period. Responses from the messages will be recorded and monitored by the study team to enhance the behavioral counseling intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Description: Participants will engage in four phone calls with the study counselor to discuss behavioral several topics (physical activity, sleep, fatigue \& dietary patterns) and to reflect on their data recorded by the FitBit devices. The calls will take place on a bi-weekly basis. During the weeks between calls, the counselor will maintain contact with the participants through asynchronous text messages to monitor their progress in the study.
Study: NCT01695993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expectancy-enhancing handout
Description: The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
Study: NCT00558467

Intervention type: DRUG
Group type: OTHER
Intervention: pramipexole immediate release (IR)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04644302

Intervention type: DIAGNOSTIC_TEST
Intervention: microcirculation recording
Description: non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws

Intervention type: DIAGNOSTIC_TEST
Intervention: microcirculation recording
Description: non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws
Study: NCT04340037

Intervention type: PROCEDURE
Intervention: percutaneous nephrolithotomy
Description: percutaneous surgery using nephroscope
Study: NCT04539184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Style Acupuncture Treatment (MSAT)
Description: MSAT required a part of the patient's body to move passively or actively while acupuncture needles are retained.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: General acupuncture
Study: NCT02189005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study dietary supplement (PreCrea 600 mg capsules)
Description: Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03526250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01695993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancy-enhancing MP3
Description: Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
Study: NCT04299698

Intervention type: BEHAVIORAL
Intervention: lifestyle
Description: Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.

Intervention type: BEHAVIORAL
Intervention: lifestyle
Description: Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.

Intervention type: BEHAVIORAL
Intervention: lifestyle
Description: Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.

Intervention type: BEHAVIORAL
Intervention: lifestyle
Description: Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.
Study: NCT04457583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with powerbreathe
Description: Participants will be submitted to a linear pressure resistance (Powerbreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 exercises for 12 weeks.
Study: NCT03941990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed 50:50 mixture of nitrous oxide and oxygen
Description: Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inhale medical air (22% O2 - 78% N2)
Study: NCT02628613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus Epirubicin
Description: Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel plus Epirubicin
Description: standard neoadjuvant chemotherapy
Study: NCT02567227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Computer, multimedia and group based health education programs.
Study: NCT02379078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision-making aid
Description: The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Generic hard copy diabetes resources
Description: A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
Study: NCT04454047

Intervention type: PROCEDURE
Intervention: Extracapsular arthroscopy
Description: Extracapsular arthroscopy method was used to treat refractory tennis elbow
Study: NCT00951743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adaptavir (monomeric DAPTA)
Description: Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adaptavir (monomeric DAPTA)
Description: Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day.
Study: NCT02402387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral head position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexed head position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended head position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotated head position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q SP Airway

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q SP Airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q SP Airway

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q SP Airway
Study: NCT03793114

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cosyntropin stimulation test
Description: Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cosyntropin stimulation test
Description: Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cosyntropin stimulation test
Description: Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Baseline blood tests
Description: Medication-fasting morning levels of adrenocortical hormones.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Baseline blood tests
Description: Medication-fasting morning levels of adrenocortical hormones.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30-hour ambulatory sampling of intestinal fluid
Description: 30-hour ambulatory sampling of intestinal fluid for analysis of adrenocortical hormones.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Cardiovascular and inflammatory biomarker profiles
Study: NCT04791722

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Intervention
Description: The investigators will conduct an adaptive intervention using six key implementation strategies identified in earlier research on the experiences of public housing authorities adopting a smoke-free housing policy: resident engagement, smoking cessation support, smoker compliance strategies, smoke-free policy enforcement, staff training and community partnership development. The implementation approach will be tailored for each property by varying the order and intensity of smoke-free policy implementation approaches. The design will determine the optimal plan for utilizing the six implementation strategies by learning from the challenges and successes of other properties (previous waves) and providing support to property managers to refine an implementation plan.
Study: NCT01882322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study: NCT02379078

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Generic online diabetes resources
Description: Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
Study: NCT02745184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lung stem cells
Description: Patients will receive 0.5-5x10\^6 (0.5-5 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
Study: NCT01029418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 and sorafenib
Description: dose escalation of AZD6244; sorafenib 400mg bd
Study: NCT06086665

Intervention type: DRUG
Intervention: Niraparib
Description: Niraparib

Intervention type: DRUG
Intervention: Niraparib
Description: Niraparib

Intervention type: DRUG
Intervention: Niraparib
Description: Niraparib
Study: NCT02103816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartLipo Triplex laser system along with the SideLaze800 hand piece
Study: NCT02899676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological testing
Study: NCT04791722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Intervention
Description: The investigators will conduct an adaptive intervention using six key implementation strategies identified in earlier research on the experiences of public housing authorities adopting a smoke-free housing policy: resident engagement, smoking cessation support, smoker compliance strategies, smoke-free policy enforcement, staff training and community partnership development. The implementation approach will be tailored for each property by varying the order and intensity of smoke-free policy implementation approaches. The design will determine the optimal plan for utilizing the six implementation strategies by learning from the challenges and successes of other properties (previous waves) and providing support to property managers to refine an implementation plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Intervention
Description: The investigators will conduct an adaptive intervention using six key implementation strategies identified in earlier research on the experiences of public housing authorities adopting a smoke-free housing policy: resident engagement, smoking cessation support, smoker compliance strategies, smoke-free policy enforcement, staff training and community partnership development. The implementation approach will be tailored for each property by varying the order and intensity of smoke-free policy implementation approaches. The design will determine the optimal plan for utilizing the six implementation strategies by learning from the challenges and successes of other properties (previous waves) and providing support to property managers to refine an implementation plan.
Study: NCT00086684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium 100 mg
Description: One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium 100 mg
Description: One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks